Compare · CAI vs LH
CAI vs LH
Side-by-side comparison of Caris Life Sciences Inc. (CAI) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CAI and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- LH is the larger of the two at $30.08B, about 4.6x CAI ($6.61B).
- LH has been more active in the news (11 items in the past 4 weeks vs 4 for CAI).
- LH has more recent analyst coverage (25 ratings vs 16 for CAI).
- Company
- Caris Life Sciences Inc.
- Labcorp Holdings Inc.
- Price
- -
- -
- Market cap
- $6.61B
- $30.08B
- 1M return
- -
- +16.36%
- 1Y return
- -
- +41.74%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 4
- 11
- Recent ratings
- 16
- 25
Caris Life Sciences Inc.
CAI International, Inc. operates as a transportation finance company in the United States, Switzerland, France, Korea, Singapore, rest of Asia, rest of Europe, and internationally. The company leases, re-leases, and disposes equipment; and contracts for the repair, repositioning, and storage of equipment. It leases its container equipment to lessees under long-term, short-term, and finance leases. The company also sells containers; and manages equipment for to third-party investors, as well as sells used containers. As of December 31, 2020, it had a container fleet comprised 1,798,520 cost equivalent units. The company was formerly known as Container Applications International, Inc. and changed its name to CAI International, Inc. in February 2007. CAI International, Inc. was incorporated in 1989 and is headquartered in San Francisco, California.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest CAI
- Amendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.
- SEC Form 10-Q filed by Caris Life Sciences Inc.
- Caris Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
- Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection
- Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
- Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026
- Officer Denton John Russel sold $238,626 worth of shares (7,500 units at $31.82), decreasing direct ownership by 4% to 174,855 units (SEC Form 4)
- Officer Brille Brian J exercised 400,000 shares at a strike of $2.44 and sold $12,132,080 worth of shares (400,000 units at $30.33) (SEC Form 4)
- Caris Life Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
Latest LH
- EVP, Pres of BLS, CMO & CSO Caveney Brian J sold $744,080 worth of shares (2,000 units at $372.04), decreasing direct ownership by 5% to 34,562 units (SEC Form 4)
- EVP and President, Diagnostics Vaughn Bryan T sold $108,232 worth of shares (306 units at $353.70) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 6,845 units (SEC Form 4)
- Labcorp Holdings Inc. upgraded by HSBC Securities with a new price target
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Speak at the UBS Global Healthcare Conference
- Director Parham Richelle P sold $389,395 worth of shares (1,078 units at $361.22), decreasing direct ownership by 32% to 2,288 units (SEC Form 4)
- EVP, CIO & CTO Oyegunwa Akinbolade converted options into 370 shares and covered exercise/tax liability with 118 shares, increasing direct ownership by 5% to 5,316 units (SEC Form 4) to satisfy tax liability
- EVP and President, Diagnostics Vaughn Bryan T converted options into 500 shares and covered exercise/tax liability with 194 shares, increasing direct ownership by 4% to 7,151 units (SEC Form 4) to cover taxes
- SEC Form 10-Q filed by Labcorp Holdings Inc.
- SEC Form 8-K filed by Labcorp Holdings Inc.